Profile cover photo
Profile photo
Mendy Schurder
224 followers -
Supplying API's Today, For Tomorrow's Innovative Drug Therapies
Supplying API's Today, For Tomorrow's Innovative Drug Therapies

224 followers
About
Mendy's posts

Post has shared content
Known as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults and adolescents ages 12 to 17.

Read it here: http://www.lgmpharma.com/blog/almotriptan-patent-to-expire-in-may-2015/

Pin it for later: https://www.pinterest.com/pin/248472104417930624/

Post has attachment
Known as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults and adolescents ages 12 to 17.

Read it here: http://www.lgmpharma.com/blog/almotriptan-patent-to-expire-in-may-2015/

Pin it for later: https://www.pinterest.com/pin/248472104417930624/

Post has shared content
News report: ‘Liquid biopsies’ could help spot genetic faults in lung cancer. Find out more: http://bit.ly/1E30ScZ 
Photo

Post has attachment

Post has shared content

Post has attachment
Concerns for patients with myelodysplastic syndrome (MDS) being administered this potent anti-cancer drug were quelled, when a comprehensive study revealed that this lifesaving treatment did not lead to a transformation to AML in Lenalidomide patients. #leukemia #lymphoma #cancer   http://www.lgmpharma.com/blog/increased-risk-aml-lenalidomide-drug-recipients/

Post has attachment

Pancreatic Cancer Predicted to Become the Second Cause of U.S. Cancer Deaths - A report issued from the Pancreatic Cancer Action Network predicted that pancreatic cancer will become the #2 cause of cancer deaths by 2030 http://www.lgmpharma.com/blog/pancreatic-cancer-predicted-become-second-cause-u-s-cancer-deaths/

Idelalisib Is a Leader in Oncology Treatment - A green light for Idelalisib is expected later this summer as this unique P13K delta inhibitor has proven viable both as a single agent and in combination with other anti- cancer drugs. http://www.lgmpharma.com/blog/idelalisib-leader-oncology-treatment/

Erdosteine Attains Orphan-Drug Status from the FDA - There are currently no medications approved in the United States for the treatment of Bronchiectasis, therefore the ultimate approval of Erdosteine would be beneficial for this urgent unmet need. http://www.lgmpharma.com/blog/erdosteine-attains-orphan-drug-status-fda/
Wait while more posts are being loaded